David A. Spellman's most recent trade in Akebia Therapeutics Inc. was a trade of 63,567 Common Stock done at an average price of $1.1 . Disclosure was reported to the exchange on May 16, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 1.07 per share. | 16 May 2023 | 63,567 | 446,483 (0%) | 0% | 1.1 | 67,890 | Common Stock |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 01 Mar 2023 | 6,400 | 510,860 (0%) | 0% | 0.9 | 5,616 | Common Stock |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 01 Mar 2023 | 810 | 510,050 (0%) | 0% | 0.9 | 711 | Common Stock |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 0.81 per share. | 27 Feb 2023 | 7,539 | 517,260 (0%) | 0% | 0.8 | 6,131 | Common Stock |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 294,300 | 294,300 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 196,200 | 524,799 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 200,000 | 200,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 200,000 | 328,599 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 225,000 | 225,000 | - | - | Employee Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 60,000 | 129,402 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 2.15 per share. | 28 Feb 2022 | 7,400 | 69,402 (0%) | 0% | 2.2 | 15,946 | Common Stock |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 28 Feb 2022 | 803 | 128,599 (0%) | 0% | 2.2 | 1,743 | Common Stock |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 200,000 | 200,000 | - | - | Employee Stock Option (Right to Buy) | |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 3.40 per share. | 01 Apr 2021 | 790 | 76,802 (0%) | 0% | 3.4 | 2,686 | Common Stock |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2021 | 7,592 | 77,592 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 120,000 | 120,000 | - | - | Employee Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | David A. Spellman | SVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 70,000 | 70,000 (0%) | 0% | 0 | Common Stock |